Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) Short Interest Update

Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) saw a significant growth in short interest in February. As of February 15th, there was short interest totalling 900 shares, a growth of 125.0% from the January 31st total of 400 shares. Based on an average daily volume of 13,500 shares, the short-interest ratio is presently 0.1 days.

Scinai Immunotherapeutics Price Performance

NASDAQ:SCNI remained flat at $3.54 during mid-day trading on Friday. The company’s stock had a trading volume of 1,969 shares, compared to its average volume of 14,584. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.16 and a current ratio of 1.16. The company has a 50 day moving average of $3.47 and a two-hundred day moving average of $3.52. The company has a market cap of $3.02 million, a price-to-earnings ratio of -0.01 and a beta of 2.37. Scinai Immunotherapeutics has a twelve month low of $2.23 and a twelve month high of $8.92.

Scinai Immunotherapeutics Company Profile

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications.